FDAsafety guidance72% confidence
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (asthma) as AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Respiratory · Asthma
- Sub-indication
- Asthma
Related signal: AstraZeneca's PT010 Study Targets Severe Asthma in Adults and Adolescents